Log in

NYSE:XCURExicure Stock Price, Forecast & News

$2.44
-0.06 (-2.40 %)
(As of 07/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.34
Now: $2.44
$2.51
50-Day Range
$2.35
MA: $2.74
$3.15
52-Week Range
$0.96
Now: $2.44
$3.84
Volume327,300 shs
Average Volume363,339 shs
Market Capitalization$212.65 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Exicure, Inc., a clinical-stage biotechnology company, develops gene regulatory and immuno-oncology therapeutics based on spherical nucleic acid (SNA) technology. Its three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA that targets TNF for the treatment of mild to moderate psoriasis. The company has collaboration agreement with Purdue Pharma L.P. Purdue Pharma for the development of AST-005; and license and development agreement DERMELIX, LLC, d/b/a Dermelix Biotherapeutics to research, develop, and commercialize Exicure's technology for the treatment of Netherton Syndrome and for five additional rare skin indications. Exicure, Inc. was founded in 2011 and is headquartered in Skokie, Illinois.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.60 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone847-673-1700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees30
Market Cap$212.65 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive XCUR News and Ratings via Email

Sign-up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter.

Exicure (NYSE:XCUR) Frequently Asked Questions

How has Exicure's stock been impacted by COVID-19 (Coronavirus)?

Exicure's stock was trading at $1.66 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, XCUR stock has increased by 47.0% and is now trading at $2.44. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Exicure?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exicure in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Exicure.

When is Exicure's next earnings date?

Exicure is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Exicure.

How were Exicure's earnings last quarter?

Exicure, Inc. (NYSE:XCUR) announced its earnings results on Thursday, May, 14th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.15. The company earned $9.18 million during the quarter, compared to analysts' expectations of $0.40 million. View Exicure's earnings history.

Has Exicure been receiving favorable news coverage?

News coverage about XCUR stock has been trending very negative recently, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Exicure earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Exicure.

Who are some of Exicure's key competitors?

What other stocks do shareholders of Exicure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exicure investors own include JD.Com (JD), Roku (ROKU), Tesla (TSLA), Aurora Cannabis (ACB), Agree Realty (ADC), Alexion Pharmaceuticals (ALXN), Alphatec (ATEC), Alibaba Group (BABA), Biogen (BIIB) and Berkshire Hathaway (BRK.B).

Who are Exicure's key executives?

Exicure's management team includes the following people:
  • Dr. Chad A. Mirkin Ph.D., Co-Founder & Chairman (Age 55)
  • Dr. David A. Giljohann, CEO & Director (Age 38)
  • Mr. David S. Snyder, Chief Financial Officer (Age 59)
  • Dr. Matthias G. Schroff, Chief Operating Officer (Age 51)

What is Exicure's stock symbol?

Exicure trades on the New York Stock Exchange (NYSE) under the ticker symbol "XCUR."

How do I buy shares of Exicure?

Shares of XCUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Exicure's stock price today?

One share of XCUR stock can currently be purchased for approximately $2.44.

How big of a company is Exicure?

Exicure has a market capitalization of $212.65 million. Exicure employs 30 workers across the globe.

What is Exicure's official website?

The official website for Exicure is www.exicuretx.com.

How can I contact Exicure?

The company can be reached via phone at 847-673-1700.

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.